A Multicenter Randomized Controlled Clinical Study of Neoadjuvant Combination of Axitinib Plus PD-1 Monoclonal Antibody to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Latest Information Update: 11 May 2023
At a glance
- Drugs Axitinib (Primary) ; Toripalimab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
Most Recent Events
- 04 May 2023 Status changed from not yet recruiting to recruiting.
- 28 Mar 2023 Planned initiation date changed from 16 Mar 2023 to 16 Apr 2023.
- 16 Mar 2023 Planned number of patients changed from 110 to 246.